Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $7.3 million.

  • Prime Medicine's Capital Expenditures fell 80.66% to $247,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 17.85%. This contributed to the annual value of $7.3 million for FY2024, which is 16.39% down from last year.
  • Per Prime Medicine's latest filing, its Capital Expenditures stood at $7.3 million for FY2024, which was down 16.39% from $8.7 million recorded in FY2023.
  • Over the past 5 years, Prime Medicine's Capital Expenditures peaked at $16.1 million during FY2022, and registered a low of $639,000 during FY2020.
  • In the last 3 years, Prime Medicine's Capital Expenditures had a median value of $8.7 million in 2023 and averaged $10.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 549.45% in 2021, then tumbled by 45.80% in 2023.
  • Prime Medicine's Capital Expenditures (Yearly) stood at $639,000 in 2020, then skyrocketed by 549.45% to $4.2 million in 2021, then surged by 287.83% to $16.1 million in 2022, then plummeted by 45.80% to $8.7 million in 2023, then fell by 16.39% to $7.3 million in 2024.